Mohammad Azab - Xenon Pharmaceuticals Director
| XENE Stock | USD 40.50 0.40 1.00% |
Director
Dr. Mohammad Azab is an Independent Director of Xenon Pharmaceuticals Inc. Dr. Azab was the Chief Medical Officer of Astex Pharmaceuticals, Inc., a pharmaceutical company focused on the discovery and development of drugs in oncology and other areas, since July 2009 and was President and Chief Medical Officer of Astex since January 2014. Prior to joining Astex, he was with Intradigm Corporationrationration, a developer of RNAi therapeutics acquired by Silence Therapeutics PLC, where he served as President and Chief Executive Officer from July 2006 until November 2008 and as a director from July 2006 until January 2010. Prior to Intradigm Corporationrationration, he served as Executive Vice President, of Research and Development and Chief Medical Officer for QLT Inc., and held several senior positions at AstraZeneca and Sanofi since 2003.
| Age | 62 |
| Tenure | 21 years |
| Professional Marks | MBA |
| Address | 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 |
| Phone | 604 484 3300 |
| Web | https://www.xenon-pharma.com |
Xenon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1557) % which means that it has lost $0.1557 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2212) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals' management efficiency ratios could be used to measure how well Xenon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of April 26, 2024, Return On Tangible Assets is expected to decline to -0.2. In addition to that, Return On Capital Employed is expected to decline to -0.24. At present, Xenon Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 677.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 4.1 M.Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.16 |
Xenon Pharmaceuticals Leadership Team
Elected by the shareholders, the Xenon Pharmaceuticals' board of directors comprises two types of representatives: Xenon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenon. The board's role is to monitor Xenon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xenon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher MD, Chief Officer | ||
| Michael Hayden, Director | ||
| Andrea JD, Chief Secretary | ||
| Karen Corraini, General Counsel and Corporate Secretary | ||
| Dawn Svoronos, Director | ||
| Simon Pimstone, President CEO, Director | ||
| Gary Patou, Director | ||
| James Empfield, Senior Vice President - Drug Discovery | ||
| CMA CPA, CEO Pres | ||
| Richard Scheller, Director | ||
| Michael Tarnow, Chairman of the Board | ||
| Ian Mortimer, CFO, COO | ||
| MBA MSc, Ex Operations | ||
| Mohammad Azab, Director | ||
| MBA MPH, Chief Officer | ||
| Gary Bridger, Executive Vice-President of RandD | ||
| Yigal Goldberg, Vice President of Clinical Development | ||
| Sherry Aulin, Chief Officer | ||
| Frank Holler, Board Member | ||
| Ernesto AycardiFonseca, Chief Medical Officer | ||
| Steven Gannon, Director | ||
| Robin Sherrington, Sr. VP of Bus. and Corporate Devel. | ||
| Charles Cohen, VP of Biology | ||
| Ernesto Aycardi, Chief Medical Officer | ||
| Shelley BA, Executive Resources |
Xenon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 2.35 B | ||||
| Shares Outstanding | 75.43 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 2.62 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 3.35 X | ||||
| Price To Sales | 181.44 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets |
Is Xenon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.73) | Quarterly Revenue Growth (1.00) | Return On Assets (0.16) | Return On Equity (0.22) |
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.